Moderna says its combination Covid and flu vaccine works well in late-stage trial
Moderna said on Monday its combination vaccine to protect against both Covid and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial.
Moderna said on Monday its combination vaccine to protect against both Covid and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial.
In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional flu vaccines and Moderna’s Spikevax mRNA Covid shot, the company said.
The vaccine, called mRNA-1083, elicited a higher immune response against two A strains and one B strain of the flu in older adults when compared with widely used flu shots from GlaxoSmithKline and Sanofi, according to the company.
The Food and Drug Administration in March recommended drugmakers target those three strains, called H1N1, H3N2, and B/Victoria, when developing their seasonal flu vaccines for 2024.
The latest data was collected from two arms of a larger study that involved around 8,000 people — one tested the combination against GSK’s Fluarix in adults aged 50 to 64 and another against Sanofi’s Fluzone HD in people 65 and older. Fluzone is a high-dose vaccine for older people.
Rating: 5